Natera director Sheena’s trusts dispose of $7.0m in NTRA stock
Jonathan Sheena, a director of Natera (NTRA), saw trusts associated with him sell $7.0m in NTRA stock on September 23, 2026. The stock has gained 153% over the past year, trading near its 52-week high. Natera reported Q2 2026 revenue of $753m, exceeding estimates, and raised its full-year guidance. RBC Capital increased its price target to $460, while Rothschild Redburn initiated coverage with a Buy rating and a $385 target.
How this was made
The 30-second read
Why it matters
The insider sale adds short‑term supply pressure but is mitigated by the company's positive earnings momentum and analyst support.
Market read
Primary disclosure of a $7M insider sale; relevant for short‑term traders monitoring supply dynamics amid strong fundamentals.
What to watch
Recent strong Q2 results and upgraded price targets may offset any negative sentiment from the insider sale.
Background
Natera reported strong Q2 2026 results, raised guidance, and received analyst upgrades, while the director's trusts disposed of shares under a 10b5‑1 plan.
Ticker impact
Form 4 filing shows director trusts sold $7.0M of NTRA shares on Sep 23, 2026 under a 10b5‑1 plan.
Possible modest downside of 1‑2% over the next few days as the market digests the sale.
Sale size is material for a mid‑cap biotech, disclosed for the first time, but the director used a pre‑arranged plan, limiting negative inference.
Market effects
Biotech sector may see heightened scrutiny of insider activity, but no broader impact.
Limited to US markets where NTRA trades.
Minimal; the filing is company‑specific.
Counterpoint
The sale could be purely liquidity‑driven and not indicative of future performance; the stock may continue its uptrend.
Key entities
- companyNatera, Inc.
US‑listed biotech (NASDAQ:NTRA) specializing in genetic testing.
- individualJonathan Sheena
Director and co‑founder of Natera, filing a Form 4 sale.
